Neurizon Enters Global Licensing Agreement with Elanco
Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited on 6ix
In the deck
Earlier from Neurizon Therapeutics
- Neurizon develops liquid formulation of NUZ-001
- NUZ-001 Shows Significant Blood-Brain Barrier Penetration
- NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
- NUZ-001 Shows Promise in a Model of Huntington's Disease
- Last Patient Successfully Completes Treatment in OLE Study
Later from Neurizon Therapeutics
- Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
- Positive feedback from FDA on strategy to lift clinical hold
- Neurizon Submits Clinical Hold Complete Response to FDA
- Neurizon Secures Loan Against 2025 R&D Tax Rebate
- FDA Review Timeline Extended for NUZ-001 IND Clinical Hold
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics